Nancy Dumont

Broad Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index6.5kcitations127works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

TGF-β signaling in diseases(23), Cancer-related Molecular Pathways(19), Monoclonal and Polyclonal Antibodies Research(17), Ubiquitin and proteasome pathways(17), HER2/EGFR in Cancer Research(13)

Publications127 total

Supplementary Figures and Tables from A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas
2025Open Access
Supplemental Figure 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Table 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Table 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Figure 7 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Figure 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Table 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Table 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Table 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Figure 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Figure 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Figure 6 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Data from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Supplemental Figure 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025Open Access
Identification of small molecule inhibitors of PPM1D using an integrated drug discovery platform
iScience·2025Open Access
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Molecular Cancer Therapeutics·2024· 13 citedOpen Access
295 (PB283): Predictive Markers of Response to the MDM2 Degrader KT-253
European Journal of Cancer·2024· 1 cited
Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform
2024Open Access
P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.
HemaSphere·2023· 1 citedOpen Access
Data from A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Francisca Vázquez(14), Todd R. Golub(12), David E. Root(12), Carlos L. Arteaga(11), Alfredo González(9), James M. McFarland(8), Jesse S. Boehm(8), Thea D. Tlsty(7), Joshua M. Dempster(7), Federica Piccioni(7), William C. Hahn(7), Brenton R. Paolella(7), Michael Rothberg(7), Mai Abdusamad(7), Aviad Tsherniak(6), John M. Krill-Burger(5), Elena Geretti(5), Thomas J. Wickham(5), Neekesh V. Dharia(5), Guillaume Kugener(5)